ADMA Biologics (ADMA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
1 Jul, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who welcomed attendees to the virtual format and outlined the process for conducting official business.
Legal and technical formalities were addressed to ensure the meeting was duly authorized, including the appointment of the Inspector of Election.
The agenda included the introduction of directors, officers, and the independent accounting firm, as well as the presentation of proposals for shareholder consideration.
Board and executive committee updates
Directors and officers were introduced, including new and continuing members, and representatives from the independent accounting firm were presented.
Shareholder proposals
Three proposals were presented: election of Class I Directors, ratification of the independent accounting firm, and a non-binding advisory vote on executive compensation.
Latest events from ADMA Biologics
- ASCENIV growth and margin gains offset BIVIGAM declines amid IG market disruption.ADMA
Q1 202612 May 2026 - Votes will be cast on director elections, auditor ratification, and executive pay approval.ADMA
Proxy filing15 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with Board support.ADMA
Proxy filing15 Apr 2026 - 2025 revenue up 20% to $510M, with 2026 guidance above $635M and strong margin growth.ADMA
Q4 202512 Apr 2026 - Q2 2024 revenue up 78% to $107.2M, net income $32.1M, guidance raised on ASCENIV growth.ADMA
Q2 20242 Feb 2026 - Directors and auditor were elected and ratified with strong support at the virtual meeting.ADMA
AGM 202431 Jan 2026 - ASCENIV's growth, margin expansion, and robust IP position signal a strong outlook.ADMA
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 2024 revenue up 78% and net income up 1,300%, with raised guidance for 2024–25.ADMA
Q3 202415 Jan 2026 - Yield enhancement and ASCENIV growth drive record revenue, margin expansion, and future potential.ADMA
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026